Galapagos Achieves Milestone in Osteoporosis Collaboration with Lilly
News Jul 23, 2009
Galapagos NV has announced that it has reached a milestone in its osteoporosis collaboration with Eli Lilly and Company, triggering a payment of €2.5 million from Lilly.
In December 2007, Lilly and Galapagos initiated an alliance to develop new medicines for the treatment of osteoporosis. The agreement provides Lilly access to 12 of Galapagos' novel target based programs in osteoporosis, with Galapagos responsible for the development of drug candidates through to Phase IIa clinical Proof of Concept.
The milestone announced is the result of one of these programs reaching the next phase of medicinal chemistry optimization. To date, Galapagos has received a total of €3.9 million in milestone payments from Lilly under the alliance.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Researchers Find a Way to Separate Side Effects of Opioid Drugs Reducing RiskNews
Scientists have discovered a way to separate these two effects -- pain relief and breathing, opening a window of opportunity to make effective pain medications without the risk of respiratory failure.READ MORE